Updates are available Correction dated 2023-02-28
Click to view Correction: https://doi.org/10.1038/s41398-023-02377-7
-
Authors
Danyeli, Lena Vera
Sen, Zümrüt Duygu
Colic, Lejla
Kurzweil, Lisa
Gensberger-Reigl, Sabrina https://orcid.org/0000-0001-5104-9603
Macharadze, Tamar
Götting, Florian https://orcid.org/0000-0002-4800-9931
Refisch, Alexander https://orcid.org/0000-0002-3505-1575
Liebe, Thomas
Chand, Tara
Kretzschmar, Moritz https://orcid.org/0000-0002-5285-2737
Wagner, Gerd https://orcid.org/0000-0003-2296-0259
Opel, Nils https://orcid.org/0000-0003-4749-3298
Jollant, Fabrice
Speck, Oliver
Munk, Matthias H. J.
Li, Meng
Walter, Martin https://orcid.org/0000-0001-7857-4483
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (SFB779/A06)
Interdisciplinary Center of Clinical Research of the Medical Faculty Jena
- License Information
-
More Information
Article History
Received: 30 June 2022
Revised: 20 January 2023
Accepted: 30 January 2023
First Online: 16 February 2023
Change Date: 28 February 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41398-023-02377-7
Competing interests
: MW is a member of the following advisory boards and gave presentations to the following companies: Bayer AG, Germany; Boehringer Ingelheim, Germany; and Biologische Heilmittel Heel GmbH, Germany. MW has further conducted studies with institutional research support from HEEL and Janssen Pharmaceutical Research for a clinical trial (IIT) on ketamine in patients with MDD, unrelated to this investigation. MW did not receive any financial compensation from the companies mentioned above. All other authors report no biomedical financial interests or other potential conflicts of interest.
